T-CURX announces $20M Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral in vivo CAR-T platform
Würzburg, Dec 17. 2026 - T-CURX GmbH (T-CURX) today announces the first closing of a $ 20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors for accelerating clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX’s proprietary non-viral technologies for in vivo CAR-T generation.
The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund as additional investors, along with existing and new individual investors.
Ulf Grawunder, PhD, co-founder and CEO of T-CURX, commented on the closing of this Series A financing round for T-CURX:
“I am very excited that T-CURX attracted such a high-profile, international investor syndicate, led by BiomedVC, for financing T-CURX’s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament to the high quality of T-CURX’s data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications addressing novel targets. It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, to “democratize” CAR-T therapies for patients globally.”
Aristotelis Nastos, PhD, Managing Partner and Investment Director at lead investor BiomedVC adds:
“I am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX. We were deeply impressed by the data on non-viral CAR-T product and technology development at T-CURX, the track record and experience of T-CURX founders and management team, and the promise T-CURX’ non-viral CAR-T technologies hold for making CAR-T therapies accessible and affordable for many cancer patients globally. We are very much looking forward to supporting T-CURX to achieve all of their therapeutic and commercial ambitions”